,address1,address2,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationMean,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,revenuePerShare,returnOnAssets,returnOnEquity,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,3730 Kirby Drive,Suite 1200,Houston,TX,77098,United States,281 454 3424,https://www.bellicum.com,Biotechnology,Healthcare,"Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.",13,"{'maxAge': 1, 'name': 'Mr. Charles S. Grass', 'age': 62, 'title': 'Principal Accounting Officer', 'yearBorn': 1960, 'exercisedValue': 0, 'unexercisedValue': 0}",1577750400,86400,4,0.39,0.39,0.26,0.39,0.39,0.39,0.26,0.39,0.0,1.395573,-0.39583334,24613,24613,29169,12261,12261,0.0,0.0,800,800,3608594,0.181,1.5,2.3929667,0.4086224,0.62610555,0.0,0.0,USD,23289594,0.0,8423501,9496300,1439128,90999,1681430400,1684108800,0.1515,0.0123000005,0.25054002,0.17,0.1708,-2.3,1672444800,1703980800,1688083200,-28828000,-0.91,-0.96,1:10,1580947200,15.444,-0.771,PNK,EQUITY,BLCM,BLCM,BELLICUM PHARMACEUTICALS,"Bellicum Pharmaceuticals, Inc.",1418913000,America/New_York,EDT,-14400000,0.38,3.0,hold,7410000,0.78,-30209000,0,2.128,2.502,1508000,0.049,-0.83312,-1.54474,-15804625,-27239000,0.0,0.0,-20.0378,USD,
1,3730 Kirby Drive,Suite 1200,Houston,TX,77098,United States,281 454 3424,https://www.bellicum.com,Biotechnology,Healthcare,"Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.",13,"{'maxAge': 1, 'name': 'Mr. Joseph  Senesac', 'age': 52, 'title': 'Sr. VP of Technical Operations & Quality', 'yearBorn': 1970, 'exercisedValue': 0, 'unexercisedValue': 0}",1577750400,86400,4,0.39,0.39,0.26,0.39,0.39,0.39,0.26,0.39,0.0,1.395573,-0.39583334,24613,24613,29169,12261,12261,0.0,0.0,800,800,3608594,0.181,1.5,2.3929667,0.4086224,0.62610555,0.0,0.0,USD,23289594,0.0,8423501,9496300,1439128,90999,1681430400,1684108800,0.1515,0.0123000005,0.25054002,0.17,0.1708,-2.3,1672444800,1703980800,1688083200,-28828000,-0.91,-0.96,1:10,1580947200,15.444,-0.771,PNK,EQUITY,BLCM,BLCM,BELLICUM PHARMACEUTICALS,"Bellicum Pharmaceuticals, Inc.",1418913000,America/New_York,EDT,-14400000,0.38,3.0,hold,7410000,0.78,-30209000,0,2.128,2.502,1508000,0.049,-0.83312,-1.54474,-15804625,-27239000,0.0,0.0,-20.0378,USD,
2,3730 Kirby Drive,Suite 1200,Houston,TX,77098,United States,281 454 3424,https://www.bellicum.com,Biotechnology,Healthcare,"Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.",13,"{'maxAge': 1, 'name': 'Dr. Alan K. Smith Ph.D.', 'age': 64, 'title': 'Chief Scientific Officer', 'yearBorn': 1958, 'fiscalYear': 2019, 'totalPay': 536427, 'exercisedValue': 0, 'unexercisedValue': 0}",1577750400,86400,4,0.39,0.39,0.26,0.39,0.39,0.39,0.26,0.39,0.0,1.395573,-0.39583334,24613,24613,29169,12261,12261,0.0,0.0,800,800,3608594,0.181,1.5,2.3929667,0.4086224,0.62610555,0.0,0.0,USD,23289594,0.0,8423501,9496300,1439128,90999,1681430400,1684108800,0.1515,0.0123000005,0.25054002,0.17,0.1708,-2.3,1672444800,1703980800,1688083200,-28828000,-0.91,-0.96,1:10,1580947200,15.444,-0.771,PNK,EQUITY,BLCM,BLCM,BELLICUM PHARMACEUTICALS,"Bellicum Pharmaceuticals, Inc.",1418913000,America/New_York,EDT,-14400000,0.38,3.0,hold,7410000,0.78,-30209000,0,2.128,2.502,1508000,0.049,-0.83312,-1.54474,-15804625,-27239000,0.0,0.0,-20.0378,USD,
